nodes	percent_of_prediction	percent_of_DWPC	metapath
Fingolimod—S1PR1—multiple sclerosis	0.695	1	CbGaD
Fingolimod—CYP2E1—Mitoxantrone—multiple sclerosis	0.0208	0.267	CbGbCtD
Fingolimod—CYP2E1—Dexamethasone—multiple sclerosis	0.0108	0.139	CbGbCtD
Fingolimod—CYP3A4—Methylprednisolone—multiple sclerosis	0.00864	0.111	CbGbCtD
Fingolimod—CYP3A4—Triamcinolone—multiple sclerosis	0.00655	0.0841	CbGbCtD
Fingolimod—CYP3A4—Mitoxantrone—multiple sclerosis	0.0063	0.0809	CbGbCtD
Fingolimod—CYP3A4—Betamethasone—multiple sclerosis	0.00562	0.0721	CbGbCtD
Fingolimod—CYP3A4—Prednisolone—multiple sclerosis	0.00554	0.0712	CbGbCtD
Fingolimod—Death—Cladribine—multiple sclerosis	0.00544	0.0832	CcSEcCtD
Fingolimod—CYP3A4—Prednisone—multiple sclerosis	0.00524	0.0672	CbGbCtD
Fingolimod—CYP2D6—Dexamethasone—multiple sclerosis	0.00514	0.066	CbGbCtD
Fingolimod—X-linked lymphoproliferative syndrome—Azathioprine—multiple sclerosis	0.00377	0.0576	CcSEcCtD
Fingolimod—Varicella—Azathioprine—multiple sclerosis	0.00377	0.0576	CcSEcCtD
Fingolimod—Lymphoproliferative disorder—Azathioprine—multiple sclerosis	0.00377	0.0576	CcSEcCtD
Fingolimod—Herpes NOS—Cladribine—multiple sclerosis	0.00327	0.05	CcSEcCtD
Fingolimod—CYP3A4—Dexamethasone—multiple sclerosis	0.00327	0.042	CbGbCtD
Fingolimod—S1PR1—brainstem—multiple sclerosis	0.00237	0.0644	CbGeAlD
Fingolimod—Herpes virus infection—Cladribine—multiple sclerosis	0.00226	0.0345	CcSEcCtD
Fingolimod—SPHK1—retina—multiple sclerosis	0.00226	0.0615	CbGeAlD
Fingolimod—S1PR5—midbrain—multiple sclerosis	0.00206	0.056	CbGeAlD
Fingolimod—S1PR5—nervous system—multiple sclerosis	0.00169	0.0461	CbGeAlD
Fingolimod—S1PR5—central nervous system—multiple sclerosis	0.00163	0.0443	CbGeAlD
Fingolimod—S1PR5—cerebellum—multiple sclerosis	0.00159	0.0433	CbGeAlD
Fingolimod—CYP4F12—medulla oblongata—multiple sclerosis	0.00157	0.0427	CbGeAlD
Fingolimod—Lymphoproliferative disorder—Methotrexate—multiple sclerosis	0.00152	0.0232	CcSEcCtD
Fingolimod—X-linked lymphoproliferative syndrome—Methotrexate—multiple sclerosis	0.00152	0.0232	CcSEcCtD
Fingolimod—S1PR1—midbrain—multiple sclerosis	0.00151	0.041	CbGeAlD
Fingolimod—SPHK1—midbrain—multiple sclerosis	0.00149	0.0406	CbGeAlD
Fingolimod—S1PR1—spinal cord—multiple sclerosis	0.00147	0.04	CbGeAlD
Fingolimod—Lymphoma—Azathioprine—multiple sclerosis	0.00146	0.0223	CcSEcCtD
Fingolimod—Non-Hodgkin's lymphoma—Azathioprine—multiple sclerosis	0.00146	0.0223	CcSEcCtD
Fingolimod—CYP4F12—midbrain—multiple sclerosis	0.00143	0.039	CbGeAlD
Fingolimod—S1PR3—nervous system—multiple sclerosis	0.00141	0.0383	CbGeAlD
Fingolimod—CYP4F12—spinal cord—multiple sclerosis	0.0014	0.0381	CbGeAlD
Fingolimod—S1PR3—central nervous system—multiple sclerosis	0.00135	0.0369	CbGeAlD
Fingolimod—S1PR5—brain—multiple sclerosis	0.00129	0.0352	CbGeAlD
Fingolimod—S1PR1—nervous system—multiple sclerosis	0.00124	0.0337	CbGeAlD
Fingolimod—SPHK1—nervous system—multiple sclerosis	0.00123	0.0334	CbGeAlD
Fingolimod—Lymphopenia—Cladribine—multiple sclerosis	0.00123	0.0187	CcSEcCtD
Fingolimod—S1PR1—central nervous system—multiple sclerosis	0.00119	0.0325	CbGeAlD
Fingolimod—Non-Hodgkin's lymphoma—Mitoxantrone—multiple sclerosis	0.00118	0.018	CcSEcCtD
Fingolimod—S1PR1—cerebellum—multiple sclerosis	0.00117	0.0318	CbGeAlD
Fingolimod—CYP4F12—cerebellum—multiple sclerosis	0.00111	0.0302	CbGeAlD
Fingolimod—S1PR3—brain—multiple sclerosis	0.00107	0.0293	CbGeAlD
Fingolimod—S1PR1—brain—multiple sclerosis	0.000947	0.0258	CbGeAlD
Fingolimod—SPHK1—brain—multiple sclerosis	0.000937	0.0255	CbGeAlD
Fingolimod—CYP4F12—brain—multiple sclerosis	0.0009	0.0245	CbGeAlD
Fingolimod—Herpes zoster—Cladribine—multiple sclerosis	0.000833	0.0127	CcSEcCtD
Fingolimod—Depressed mood—Methylprednisolone—multiple sclerosis	0.000694	0.0106	CcSEcCtD
Fingolimod—Herpes zoster—Azathioprine—multiple sclerosis	0.000677	0.0103	CcSEcCtD
Fingolimod—Liver injury—Azathioprine—multiple sclerosis	0.000606	0.00926	CcSEcCtD
Fingolimod—Lymphoma—Methotrexate—multiple sclerosis	0.000588	0.00898	CcSEcCtD
Fingolimod—Gamma-glutamyltransferase increased—Mitoxantrone—multiple sclerosis	0.000501	0.00766	CcSEcCtD
Fingolimod—Lymphopenia—Prednisone—multiple sclerosis	0.00048	0.00734	CcSEcCtD
Fingolimod—Visual acuity reduced—Dexamethasone—multiple sclerosis	0.000474	0.00725	CcSEcCtD
Fingolimod—Visual acuity reduced—Betamethasone—multiple sclerosis	0.000474	0.00725	CcSEcCtD
Fingolimod—Cerebrovascular accident—Cladribine—multiple sclerosis	0.000465	0.0071	CcSEcCtD
Fingolimod—Hepatic enzyme increased—Mitoxantrone—multiple sclerosis	0.000436	0.00666	CcSEcCtD
Fingolimod—Blood triglycerides increased—Prednisone—multiple sclerosis	0.000375	0.00573	CcSEcCtD
Fingolimod—Pneumonia—Cladribine—multiple sclerosis	0.000353	0.00539	CcSEcCtD
Fingolimod—Infestation NOS—Cladribine—multiple sclerosis	0.000351	0.00536	CcSEcCtD
Fingolimod—Infestation—Cladribine—multiple sclerosis	0.000351	0.00536	CcSEcCtD
Fingolimod—Connective tissue disorder—Cladribine—multiple sclerosis	0.000309	0.00473	CcSEcCtD
Fingolimod—CYP2D6—brainstem—multiple sclerosis	0.0003	0.00818	CbGeAlD
Fingolimod—SPHK1—Betamethasone—Methylprednisolone—multiple sclerosis	0.000296	0.105	CbGdCrCtD
Fingolimod—SPHK1—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000296	0.105	CbGdCrCtD
Fingolimod—Eye disorder—Cladribine—multiple sclerosis	0.000294	0.0045	CcSEcCtD
Fingolimod—Cardiac disorder—Cladribine—multiple sclerosis	0.000292	0.00447	CcSEcCtD
Fingolimod—SPHK1—Betamethasone—Dexamethasone—multiple sclerosis	0.000291	0.104	CbGdCrCtD
Fingolimod—SPHK1—Dexamethasone—Betamethasone—multiple sclerosis	0.000291	0.104	CbGdCrCtD
Fingolimod—Pneumonia—Azathioprine—multiple sclerosis	0.000287	0.00438	CcSEcCtD
Fingolimod—Angiopathy—Cladribine—multiple sclerosis	0.000286	0.00437	CcSEcCtD
Fingolimod—Infestation NOS—Azathioprine—multiple sclerosis	0.000285	0.00436	CcSEcCtD
Fingolimod—Infestation—Azathioprine—multiple sclerosis	0.000285	0.00436	CcSEcCtD
Fingolimod—SPHK1—Dexamethasone—Triamcinolone—multiple sclerosis	0.000285	0.101	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Triamcinolone—multiple sclerosis	0.000285	0.101	CbGdCrCtD
Fingolimod—Mediastinal disorder—Cladribine—multiple sclerosis	0.000284	0.00434	CcSEcCtD
Fingolimod—Alopecia—Cladribine—multiple sclerosis	0.000278	0.00425	CcSEcCtD
Fingolimod—Mental disorder—Cladribine—multiple sclerosis	0.000276	0.00422	CcSEcCtD
Fingolimod—Herpes zoster—Methotrexate—multiple sclerosis	0.000273	0.00417	CcSEcCtD
Fingolimod—SPHK1—Dexamethasone—Prednisone—multiple sclerosis	0.00027	0.0961	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Prednisone—multiple sclerosis	0.00027	0.0961	CbGdCrCtD
Fingolimod—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000269	0.00412	CcSEcCtD
Fingolimod—Back pain—Cladribine—multiple sclerosis	0.000265	0.00405	CcSEcCtD
Fingolimod—CYP2E1—medulla oblongata—multiple sclerosis	0.000264	0.0072	CbGeAlD
Fingolimod—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000264	0.00403	CcSEcCtD
Fingolimod—SPHK1—Betamethasone—Prednisolone—multiple sclerosis	0.000264	0.0938	CbGdCrCtD
Fingolimod—SPHK1—Dexamethasone—Prednisolone—multiple sclerosis	0.000264	0.0938	CbGdCrCtD
Fingolimod—Cough—Cladribine—multiple sclerosis	0.000239	0.00366	CcSEcCtD
Fingolimod—CYP2E1—spinal cord—multiple sclerosis	0.000236	0.00642	CbGeAlD
Fingolimod—Weight decreased—Mitoxantrone—multiple sclerosis	0.000234	0.00358	CcSEcCtD
Fingolimod—Cardiac arrest—Prednisolone—multiple sclerosis	0.000233	0.00357	CcSEcCtD
Fingolimod—Pneumonia—Mitoxantrone—multiple sclerosis	0.000232	0.00354	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000232	0.00354	CcSEcCtD
Fingolimod—Mediastinal disorder—Azathioprine—multiple sclerosis	0.000231	0.00353	CcSEcCtD
Fingolimod—Eye pain—Betamethasone—multiple sclerosis	0.000227	0.00347	CcSEcCtD
Fingolimod—Eye pain—Dexamethasone—multiple sclerosis	0.000227	0.00347	CcSEcCtD
Fingolimod—Alopecia—Azathioprine—multiple sclerosis	0.000226	0.00346	CcSEcCtD
Fingolimod—Infection—Cladribine—multiple sclerosis	0.000222	0.0034	CcSEcCtD
Fingolimod—Nervous system disorder—Cladribine—multiple sclerosis	0.000219	0.00335	CcSEcCtD
Fingolimod—Skin disorder—Cladribine—multiple sclerosis	0.000217	0.00332	CcSEcCtD
Fingolimod—Hepatic enzyme increased—Methotrexate—multiple sclerosis	0.000217	0.00332	CcSEcCtD
Fingolimod—Sinusitis—Mitoxantrone—multiple sclerosis	0.000216	0.00331	CcSEcCtD
Fingolimod—Cardiac arrest—Triamcinolone—multiple sclerosis	0.000215	0.00328	CcSEcCtD
Fingolimod—Cardiac arrest—Methylprednisolone—multiple sclerosis	0.000214	0.00327	CcSEcCtD
Fingolimod—Bradycardia—Mitoxantrone—multiple sclerosis	0.000211	0.00322	CcSEcCtD
Fingolimod—Hypotension—Cladribine—multiple sclerosis	0.000209	0.0032	CcSEcCtD
Fingolimod—Migraine—Betamethasone—multiple sclerosis	0.000202	0.00308	CcSEcCtD
Fingolimod—Migraine—Dexamethasone—multiple sclerosis	0.000202	0.00308	CcSEcCtD
Fingolimod—Paraesthesia—Cladribine—multiple sclerosis	0.000201	0.00307	CcSEcCtD
Fingolimod—Leukopenia—Azathioprine—multiple sclerosis	0.0002	0.00305	CcSEcCtD
Fingolimod—Dyspnoea—Cladribine—multiple sclerosis	0.000199	0.00305	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000199	0.00304	CcSEcCtD
Fingolimod—CYP2E1—nervous system—multiple sclerosis	0.000199	0.00541	CbGeAlD
Fingolimod—Influenza—Triamcinolone—multiple sclerosis	0.000195	0.00298	CcSEcCtD
Fingolimod—Cardiac arrest—Dexamethasone—multiple sclerosis	0.000195	0.00298	CcSEcCtD
Fingolimod—Cardiac arrest—Betamethasone—multiple sclerosis	0.000195	0.00298	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000193	0.00295	CcSEcCtD
Fingolimod—Fatigue—Cladribine—multiple sclerosis	0.000193	0.00295	CcSEcCtD
Fingolimod—CYP2E1—central nervous system—multiple sclerosis	0.000191	0.00521	CbGeAlD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000188	0.00288	CcSEcCtD
Fingolimod—Bronchitis—Triamcinolone—multiple sclerosis	0.000188	0.00287	CcSEcCtD
Fingolimod—CYP2E1—cerebellum—multiple sclerosis	0.000187	0.00509	CbGeAlD
Fingolimod—Alopecia—Mitoxantrone—multiple sclerosis	0.000183	0.0028	CcSEcCtD
Fingolimod—Infection—Azathioprine—multiple sclerosis	0.000181	0.00276	CcSEcCtD
Fingolimod—Skin disorder—Azathioprine—multiple sclerosis	0.000177	0.0027	CcSEcCtD
Fingolimod—Back pain—Mitoxantrone—multiple sclerosis	0.000174	0.00266	CcSEcCtD
Fingolimod—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000174	0.00265	CcSEcCtD
Fingolimod—Infestation—Methylprednisolone—multiple sclerosis	0.000174	0.00265	CcSEcCtD
Fingolimod—Bradycardia—Prednisolone—multiple sclerosis	0.000173	0.00264	CcSEcCtD
Fingolimod—Hypotension—Azathioprine—multiple sclerosis	0.00017	0.0026	CcSEcCtD
Fingolimod—Vision blurred—Mitoxantrone—multiple sclerosis	0.00017	0.0026	CcSEcCtD
Fingolimod—Cardiac arrest—Prednisone—multiple sclerosis	0.00017	0.00259	CcSEcCtD
Fingolimod—Leukopenia—Mitoxantrone—multiple sclerosis	0.000161	0.00247	CcSEcCtD
Fingolimod—Asthenia—Cladribine—multiple sclerosis	0.000161	0.00245	CcSEcCtD
Fingolimod—Weight decreased—Betamethasone—multiple sclerosis	0.00016	0.00245	CcSEcCtD
Fingolimod—Weight decreased—Dexamethasone—multiple sclerosis	0.00016	0.00245	CcSEcCtD
Fingolimod—CYP3A4—nervous system—multiple sclerosis	0.00016	0.00435	CbGeAlD
Fingolimod—Bradycardia—Triamcinolone—multiple sclerosis	0.000159	0.00243	CcSEcCtD
Fingolimod—Bradycardia—Methylprednisolone—multiple sclerosis	0.000159	0.00242	CcSEcCtD
Fingolimod—Pruritus—Cladribine—multiple sclerosis	0.000158	0.00242	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000157	0.0024	CcSEcCtD
Fingolimod—CYP2D6—nervous system—multiple sclerosis	0.000157	0.00428	CbGeAlD
Fingolimod—Cough—Mitoxantrone—multiple sclerosis	0.000157	0.0024	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000157	0.0024	CcSEcCtD
Fingolimod—Hypertension—Mitoxantrone—multiple sclerosis	0.000156	0.00238	CcSEcCtD
Fingolimod—CYP3A4—central nervous system—multiple sclerosis	0.000154	0.00419	CbGeAlD
Fingolimod—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000153	0.00234	CcSEcCtD
Fingolimod—Diarrhoea—Cladribine—multiple sclerosis	0.000153	0.00234	CcSEcCtD
Fingolimod—Cerebrovascular accident—Methotrexate—multiple sclerosis	0.000152	0.00233	CcSEcCtD
Fingolimod—CYP2E1—brain—multiple sclerosis	0.000152	0.00414	CbGeAlD
Fingolimod—CYP2D6—central nervous system—multiple sclerosis	0.000151	0.00412	CbGeAlD
Fingolimod—CYP2D6—cerebellum—multiple sclerosis	0.000148	0.00403	CbGeAlD
Fingolimod—Dizziness—Cladribine—multiple sclerosis	0.000148	0.00226	CcSEcCtD
Fingolimod—Infection—Mitoxantrone—multiple sclerosis	0.000146	0.00223	CcSEcCtD
Fingolimod—Eye disorder—Methylprednisolone—multiple sclerosis	0.000146	0.00223	CcSEcCtD
Fingolimod—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000145	0.00221	CcSEcCtD
Fingolimod—Bradycardia—Betamethasone—multiple sclerosis	0.000144	0.0022	CcSEcCtD
Fingolimod—Bradycardia—Dexamethasone—multiple sclerosis	0.000144	0.0022	CcSEcCtD
Fingolimod—Skin disorder—Mitoxantrone—multiple sclerosis	0.000143	0.00218	CcSEcCtD
Fingolimod—Angiopathy—Methylprednisolone—multiple sclerosis	0.000141	0.00216	CcSEcCtD
Fingolimod—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.00014	0.00215	CcSEcCtD
Fingolimod—Headache—Cladribine—multiple sclerosis	0.00014	0.00214	CcSEcCtD
Fingolimod—Weight decreased—Prednisone—multiple sclerosis	0.000139	0.00213	CcSEcCtD
Fingolimod—Vision blurred—Prednisolone—multiple sclerosis	0.000139	0.00213	CcSEcCtD
Fingolimod—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000138	0.0021	CcSEcCtD
Fingolimod—Hypotension—Mitoxantrone—multiple sclerosis	0.000137	0.0021	CcSEcCtD
Fingolimod—Depression—Prednisone—multiple sclerosis	0.000137	0.00209	CcSEcCtD
Fingolimod—Mental disorder—Methylprednisolone—multiple sclerosis	0.000137	0.00209	CcSEcCtD
Fingolimod—Eye disorder—Betamethasone—multiple sclerosis	0.000132	0.00202	CcSEcCtD
Fingolimod—Eye disorder—Dexamethasone—multiple sclerosis	0.000132	0.00202	CcSEcCtD
Fingolimod—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000132	0.00202	CcSEcCtD
Fingolimod—Back pain—Triamcinolone—multiple sclerosis	0.000132	0.00201	CcSEcCtD
Fingolimod—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000131	0.002	CcSEcCtD
Fingolimod—Angiopathy—Betamethasone—multiple sclerosis	0.000129	0.00196	CcSEcCtD
Fingolimod—Angiopathy—Dexamethasone—multiple sclerosis	0.000129	0.00196	CcSEcCtD
Fingolimod—Hypertension—Prednisolone—multiple sclerosis	0.000128	0.00195	CcSEcCtD
Fingolimod—Fatigue—Mitoxantrone—multiple sclerosis	0.000127	0.00194	CcSEcCtD
Fingolimod—Bradycardia—Prednisone—multiple sclerosis	0.000126	0.00192	CcSEcCtD
Fingolimod—Alopecia—Dexamethasone—multiple sclerosis	0.000125	0.00191	CcSEcCtD
Fingolimod—Alopecia—Betamethasone—multiple sclerosis	0.000125	0.00191	CcSEcCtD
Fingolimod—Diarrhoea—Azathioprine—multiple sclerosis	0.000124	0.0019	CcSEcCtD
Fingolimod—Connective tissue disorder—Prednisone—multiple sclerosis	0.000121	0.00185	CcSEcCtD
Fingolimod—Dizziness—Azathioprine—multiple sclerosis	0.00012	0.00184	CcSEcCtD
Fingolimod—CYP2D6—brain—multiple sclerosis	0.00012	0.00327	CbGeAlD
Fingolimod—Cough—Triamcinolone—multiple sclerosis	0.000119	0.00181	CcSEcCtD
Fingolimod—Hypertension—Triamcinolone—multiple sclerosis	0.000117	0.00179	CcSEcCtD
Fingolimod—Hypertension—Methylprednisolone—multiple sclerosis	0.000117	0.00179	CcSEcCtD
Fingolimod—Pneumonia—Methotrexate—multiple sclerosis	0.000116	0.00177	CcSEcCtD
Fingolimod—Eye disorder—Prednisone—multiple sclerosis	0.000115	0.00176	CcSEcCtD
Fingolimod—Infestation NOS—Methotrexate—multiple sclerosis	0.000115	0.00176	CcSEcCtD
Fingolimod—Infestation—Methotrexate—multiple sclerosis	0.000115	0.00176	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000115	0.00175	CcSEcCtD
Fingolimod—Depression—Methotrexate—multiple sclerosis	0.000115	0.00175	CcSEcCtD
Fingolimod—Headache—Azathioprine—multiple sclerosis	0.000114	0.00174	CcSEcCtD
Fingolimod—Angiopathy—Prednisone—multiple sclerosis	0.000112	0.00171	CcSEcCtD
Fingolimod—Infection—Triamcinolone—multiple sclerosis	0.00011	0.00168	CcSEcCtD
Fingolimod—Infection—Methylprednisolone—multiple sclerosis	0.00011	0.00168	CcSEcCtD
Fingolimod—Alopecia—Prednisone—multiple sclerosis	0.000109	0.00167	CcSEcCtD
Fingolimod—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000109	0.00166	CcSEcCtD
Fingolimod—Paraesthesia—Prednisolone—multiple sclerosis	0.000108	0.00166	CcSEcCtD
Fingolimod—Mental disorder—Prednisone—multiple sclerosis	0.000108	0.00165	CcSEcCtD
Fingolimod—Skin disorder—Methylprednisolone—multiple sclerosis	0.000108	0.00164	CcSEcCtD
Fingolimod—Hypertension—Dexamethasone—multiple sclerosis	0.000107	0.00163	CcSEcCtD
Fingolimod—Hypertension—Betamethasone—multiple sclerosis	0.000107	0.00163	CcSEcCtD
Fingolimod—Asthenia—Mitoxantrone—multiple sclerosis	0.000106	0.00161	CcSEcCtD
Fingolimod—Hypotension—Methylprednisolone—multiple sclerosis	0.000103	0.00158	CcSEcCtD
Fingolimod—Vision blurred—Prednisone—multiple sclerosis	0.000101	0.00155	CcSEcCtD
Fingolimod—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000101	0.00154	CcSEcCtD
Fingolimod—Infection—Dexamethasone—multiple sclerosis	0.0001	0.00153	CcSEcCtD
Fingolimod—Infection—Betamethasone—multiple sclerosis	0.0001	0.00153	CcSEcCtD
Fingolimod—Paraesthesia—Triamcinolone—multiple sclerosis	9.96e-05	0.00152	CcSEcCtD
Fingolimod—Paraesthesia—Methylprednisolone—multiple sclerosis	9.94e-05	0.00152	CcSEcCtD
Fingolimod—Dyspnoea—Triamcinolone—multiple sclerosis	9.89e-05	0.00151	CcSEcCtD
Fingolimod—Nervous system disorder—Betamethasone—multiple sclerosis	9.87e-05	0.00151	CcSEcCtD
Fingolimod—Nervous system disorder—Dexamethasone—multiple sclerosis	9.87e-05	0.00151	CcSEcCtD
Fingolimod—Eye disorder—Methotrexate—multiple sclerosis	9.64e-05	0.00147	CcSEcCtD
Fingolimod—Cardiac disorder—Methotrexate—multiple sclerosis	9.57e-05	0.00146	CcSEcCtD
Fingolimod—Fatigue—Triamcinolone—multiple sclerosis	9.57e-05	0.00146	CcSEcCtD
Fingolimod—Fatigue—Methylprednisolone—multiple sclerosis	9.54e-05	0.00146	CcSEcCtD
Fingolimod—Hypotension—Betamethasone—multiple sclerosis	9.41e-05	0.00144	CcSEcCtD
Fingolimod—Hypotension—Dexamethasone—multiple sclerosis	9.41e-05	0.00144	CcSEcCtD
Fingolimod—Angiopathy—Methotrexate—multiple sclerosis	9.36e-05	0.00143	CcSEcCtD
Fingolimod—Mediastinal disorder—Methotrexate—multiple sclerosis	9.29e-05	0.00142	CcSEcCtD
Fingolimod—Hypertension—Prednisone—multiple sclerosis	9.27e-05	0.00142	CcSEcCtD
Fingolimod—Headache—Mitoxantrone—multiple sclerosis	9.21e-05	0.00141	CcSEcCtD
Fingolimod—Alopecia—Methotrexate—multiple sclerosis	9.11e-05	0.00139	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	9.08e-05	0.00139	CcSEcCtD
Fingolimod—Paraesthesia—Dexamethasone—multiple sclerosis	9.04e-05	0.00138	CcSEcCtD
Fingolimod—Paraesthesia—Betamethasone—multiple sclerosis	9.04e-05	0.00138	CcSEcCtD
Fingolimod—Mental disorder—Methotrexate—multiple sclerosis	9.04e-05	0.00138	CcSEcCtD
Fingolimod—Infection—Prednisone—multiple sclerosis	8.71e-05	0.00133	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	8.69e-05	0.00133	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Betamethasone—multiple sclerosis	8.69e-05	0.00133	CcSEcCtD
Fingolimod—Back pain—Methotrexate—multiple sclerosis	8.68e-05	0.00133	CcSEcCtD
Fingolimod—Fatigue—Dexamethasone—multiple sclerosis	8.68e-05	0.00133	CcSEcCtD
Fingolimod—Fatigue—Betamethasone—multiple sclerosis	8.68e-05	0.00133	CcSEcCtD
Fingolimod—Nervous system disorder—Prednisone—multiple sclerosis	8.6e-05	0.00131	CcSEcCtD
Fingolimod—Skin disorder—Prednisone—multiple sclerosis	8.52e-05	0.0013	CcSEcCtD
Fingolimod—Vision blurred—Methotrexate—multiple sclerosis	8.46e-05	0.00129	CcSEcCtD
Fingolimod—Leukopenia—Methotrexate—multiple sclerosis	8.04e-05	0.00123	CcSEcCtD
Fingolimod—Dizziness—Prednisolone—multiple sclerosis	7.98e-05	0.00122	CcSEcCtD
Fingolimod—Asthenia—Triamcinolone—multiple sclerosis	7.96e-05	0.00122	CcSEcCtD
Fingolimod—Asthenia—Methylprednisolone—multiple sclerosis	7.94e-05	0.00121	CcSEcCtD
Fingolimod—Paraesthesia—Prednisone—multiple sclerosis	7.87e-05	0.0012	CcSEcCtD
Fingolimod—Pruritus—Triamcinolone—multiple sclerosis	7.85e-05	0.0012	CcSEcCtD
Fingolimod—Cough—Methotrexate—multiple sclerosis	7.83e-05	0.0012	CcSEcCtD
Fingolimod—Pruritus—Methylprednisolone—multiple sclerosis	7.83e-05	0.0012	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	7.59e-05	0.00116	CcSEcCtD
Fingolimod—Diarrhoea—Methylprednisolone—multiple sclerosis	7.57e-05	0.00116	CcSEcCtD
Fingolimod—Fatigue—Prednisone—multiple sclerosis	7.56e-05	0.00116	CcSEcCtD
Fingolimod—Headache—Prednisolone—multiple sclerosis	7.56e-05	0.00116	CcSEcCtD
Fingolimod—Dizziness—Triamcinolone—multiple sclerosis	7.34e-05	0.00112	CcSEcCtD
Fingolimod—Dizziness—Methylprednisolone—multiple sclerosis	7.32e-05	0.00112	CcSEcCtD
Fingolimod—Infection—Methotrexate—multiple sclerosis	7.28e-05	0.00111	CcSEcCtD
Fingolimod—Asthenia—Dexamethasone—multiple sclerosis	7.22e-05	0.0011	CcSEcCtD
Fingolimod—Asthenia—Betamethasone—multiple sclerosis	7.22e-05	0.0011	CcSEcCtD
Fingolimod—Nervous system disorder—Methotrexate—multiple sclerosis	7.19e-05	0.0011	CcSEcCtD
Fingolimod—Pruritus—Betamethasone—multiple sclerosis	7.12e-05	0.00109	CcSEcCtD
Fingolimod—Pruritus—Dexamethasone—multiple sclerosis	7.12e-05	0.00109	CcSEcCtD
Fingolimod—Skin disorder—Methotrexate—multiple sclerosis	7.12e-05	0.00109	CcSEcCtD
Fingolimod—Headache—Triamcinolone—multiple sclerosis	6.95e-05	0.00106	CcSEcCtD
Fingolimod—Headache—Methylprednisolone—multiple sclerosis	6.94e-05	0.00106	CcSEcCtD
Fingolimod—Diarrhoea—Dexamethasone—multiple sclerosis	6.89e-05	0.00105	CcSEcCtD
Fingolimod—Diarrhoea—Betamethasone—multiple sclerosis	6.89e-05	0.00105	CcSEcCtD
Fingolimod—Hypotension—Methotrexate—multiple sclerosis	6.85e-05	0.00105	CcSEcCtD
Fingolimod—Dizziness—Dexamethasone—multiple sclerosis	6.66e-05	0.00102	CcSEcCtD
Fingolimod—Dizziness—Betamethasone—multiple sclerosis	6.66e-05	0.00102	CcSEcCtD
Fingolimod—Paraesthesia—Methotrexate—multiple sclerosis	6.58e-05	0.00101	CcSEcCtD
Fingolimod—Dyspnoea—Methotrexate—multiple sclerosis	6.53e-05	0.000998	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Methotrexate—multiple sclerosis	6.33e-05	0.000967	CcSEcCtD
Fingolimod—Fatigue—Methotrexate—multiple sclerosis	6.32e-05	0.000965	CcSEcCtD
Fingolimod—Headache—Betamethasone—multiple sclerosis	6.31e-05	0.000964	CcSEcCtD
Fingolimod—Headache—Dexamethasone—multiple sclerosis	6.31e-05	0.000964	CcSEcCtD
Fingolimod—Asthenia—Prednisone—multiple sclerosis	6.29e-05	0.000961	CcSEcCtD
Fingolimod—Pruritus—Prednisone—multiple sclerosis	6.2e-05	0.000948	CcSEcCtD
Fingolimod—Diarrhoea—Prednisone—multiple sclerosis	6e-05	0.000917	CcSEcCtD
Fingolimod—Dizziness—Prednisone—multiple sclerosis	5.8e-05	0.000886	CcSEcCtD
Fingolimod—Headache—Prednisone—multiple sclerosis	5.49e-05	0.000839	CcSEcCtD
Fingolimod—Asthenia—Methotrexate—multiple sclerosis	5.26e-05	0.000803	CcSEcCtD
Fingolimod—Pruritus—Methotrexate—multiple sclerosis	5.18e-05	0.000792	CcSEcCtD
Fingolimod—Diarrhoea—Methotrexate—multiple sclerosis	5.01e-05	0.000766	CcSEcCtD
Fingolimod—Dizziness—Methotrexate—multiple sclerosis	4.85e-05	0.000741	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—CXCL13—multiple sclerosis	4.78e-05	0.00039	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—CXCL10—multiple sclerosis	4.77e-05	0.00039	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—CXCL10—multiple sclerosis	4.77e-05	0.00039	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—CXCL10—multiple sclerosis	4.77e-05	0.00039	CbGpPWpGaD
Fingolimod—S1PR4—GPCR downstream signaling—CCL5—multiple sclerosis	4.7e-05	0.000384	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—GPR65—multiple sclerosis	4.63e-05	0.000378	CbGpPWpGaD
Fingolimod—Headache—Methotrexate—multiple sclerosis	4.59e-05	0.000702	CcSEcCtD
Fingolimod—S1PR5—GPCR downstream signaling—CCL5—multiple sclerosis	4.53e-05	0.000369	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—CCL5—multiple sclerosis	4.53e-05	0.000369	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—CXCL10—multiple sclerosis	4.34e-05	0.000354	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.29e-05	0.00035	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.29e-05	0.00035	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—BCHE—multiple sclerosis	4.29e-05	0.00035	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—CCL5—multiple sclerosis	4.27e-05	0.000348	CbGpPWpGaD
Fingolimod—S1PR4—GPCR downstream signaling—CCR5—multiple sclerosis	4.24e-05	0.000346	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CCR1—multiple sclerosis	4.23e-05	0.000345	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CXCL13—multiple sclerosis	4.23e-05	0.000345	CbGpPWpGaD
Fingolimod—S1PR4—GPCR downstream signaling—IL2RA—multiple sclerosis	4.17e-05	0.000341	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—CCL5—multiple sclerosis	4.11e-05	0.000335	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—CCL5—multiple sclerosis	4.11e-05	0.000335	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—CCL5—multiple sclerosis	4.11e-05	0.000335	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—CCR5—multiple sclerosis	4.08e-05	0.000333	CbGpPWpGaD
Fingolimod—S1PR5—GPCR downstream signaling—CCR5—multiple sclerosis	4.08e-05	0.000333	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—IL2RA—multiple sclerosis	4.02e-05	0.000328	CbGpPWpGaD
Fingolimod—S1PR5—GPCR downstream signaling—IL2RA—multiple sclerosis	4.02e-05	0.000328	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.91e-05	0.000319	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CCL3—multiple sclerosis	3.9e-05	0.000318	CbGpPWpGaD
Fingolimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	3.89e-05	0.000318	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—CCR5—multiple sclerosis	3.85e-05	0.000314	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—IL2RA—multiple sclerosis	3.79e-05	0.000309	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—PTGER4—multiple sclerosis	3.75e-05	0.000306	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CCL3—multiple sclerosis	3.75e-05	0.000306	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CCL3—multiple sclerosis	3.75e-05	0.000306	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—CCL5—multiple sclerosis	3.73e-05	0.000305	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—CCR5—multiple sclerosis	3.7e-05	0.000302	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—CCR5—multiple sclerosis	3.7e-05	0.000302	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—CCR5—multiple sclerosis	3.7e-05	0.000302	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism—BCHE—multiple sclerosis	3.7e-05	0.000302	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—PGR—multiple sclerosis	3.7e-05	0.000302	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.69e-05	0.000301	CbGpPWpGaD
Fingolimod—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.66e-05	0.000299	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—IL2RA—multiple sclerosis	3.65e-05	0.000298	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—IL2RA—multiple sclerosis	3.65e-05	0.000298	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—IL2RA—multiple sclerosis	3.65e-05	0.000298	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CXCR3—multiple sclerosis	3.62e-05	0.000296	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—PTGER4—multiple sclerosis	3.61e-05	0.000295	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—PTGER4—multiple sclerosis	3.61e-05	0.000295	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CD28—multiple sclerosis	3.59e-05	0.000293	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—PGR—multiple sclerosis	3.56e-05	0.00029	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—PGR—multiple sclerosis	3.56e-05	0.00029	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CCR2—multiple sclerosis	3.53e-05	0.000288	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CXCR3—multiple sclerosis	3.49e-05	0.000285	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CXCR3—multiple sclerosis	3.49e-05	0.000285	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CD28—multiple sclerosis	3.46e-05	0.000282	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CD28—multiple sclerosis	3.46e-05	0.000282	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CCL3—multiple sclerosis	3.41e-05	0.000278	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CCR2—multiple sclerosis	3.39e-05	0.000277	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CCR2—multiple sclerosis	3.39e-05	0.000277	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.36e-05	0.000274	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—CCR5—multiple sclerosis	3.36e-05	0.000274	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—IL2RA—multiple sclerosis	3.31e-05	0.00027	CbGpPWpGaD
Fingolimod—S1PR4—GPCR downstream signaling—POMC—multiple sclerosis	3.31e-05	0.00027	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—PTGER4—multiple sclerosis	3.28e-05	0.000268	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CNR1—multiple sclerosis	3.25e-05	0.000266	CbGpPWpGaD
Fingolimod—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	3.25e-05	0.000265	CbGpPWpGaD
Fingolimod—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	3.25e-05	0.000265	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—PGR—multiple sclerosis	3.23e-05	0.000264	CbGpPWpGaD
Fingolimod—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	3.21e-05	0.000262	CbGpPWpGaD
Fingolimod—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	3.21e-05	0.000262	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of proteins—POMC—multiple sclerosis	3.19e-05	0.00026	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—POMC—multiple sclerosis	3.19e-05	0.00026	CbGpPWpGaD
Fingolimod—S1PR5—GPCR downstream signaling—POMC—multiple sclerosis	3.19e-05	0.00026	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—BCHE—multiple sclerosis	3.18e-05	0.000259	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CXCR3—multiple sclerosis	3.17e-05	0.000259	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CD28—multiple sclerosis	3.14e-05	0.000256	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CNR1—multiple sclerosis	3.13e-05	0.000256	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CNR1—multiple sclerosis	3.13e-05	0.000256	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of proteins—CCL2—multiple sclerosis	3.12e-05	0.000255	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CCR2—multiple sclerosis	3.08e-05	0.000252	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CCL3—multiple sclerosis	3.02e-05	0.000246	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—POMC—multiple sclerosis	3.01e-05	0.000245	CbGpPWpGaD
Fingolimod—CYP2E1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.97e-05	0.000242	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—CCL2—multiple sclerosis	2.94e-05	0.00024	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CXCL10—multiple sclerosis	2.93e-05	0.000239	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—PTGER4—multiple sclerosis	2.9e-05	0.000237	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—POMC—multiple sclerosis	2.89e-05	0.000236	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—POMC—multiple sclerosis	2.89e-05	0.000236	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—POMC—multiple sclerosis	2.89e-05	0.000236	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—PGR—multiple sclerosis	2.86e-05	0.000233	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CNR1—multiple sclerosis	2.84e-05	0.000232	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—CCL2—multiple sclerosis	2.83e-05	0.000231	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—CCL2—multiple sclerosis	2.83e-05	0.000231	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CXCL10—multiple sclerosis	2.82e-05	0.00023	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CXCL10—multiple sclerosis	2.82e-05	0.00023	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CXCR3—multiple sclerosis	2.8e-05	0.000229	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CD28—multiple sclerosis	2.78e-05	0.000227	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CCR2—multiple sclerosis	2.73e-05	0.000223	CbGpPWpGaD
Fingolimod—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	2.7e-05	0.000221	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—TYK2—multiple sclerosis	2.67e-05	0.000218	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—POMC—multiple sclerosis	2.63e-05	0.000214	CbGpPWpGaD
Fingolimod—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.6e-05	0.000212	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—APOE—multiple sclerosis	2.58e-05	0.00021	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—TYK2—multiple sclerosis	2.57e-05	0.00021	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—TYK2—multiple sclerosis	2.57e-05	0.00021	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—CCL2—multiple sclerosis	2.57e-05	0.00021	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CD86—multiple sclerosis	2.56e-05	0.000209	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CXCL10—multiple sclerosis	2.56e-05	0.000209	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CCL5—multiple sclerosis	2.52e-05	0.000206	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CNR1—multiple sclerosis	2.52e-05	0.000205	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CD86—multiple sclerosis	2.47e-05	0.000201	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CD86—multiple sclerosis	2.47e-05	0.000201	CbGpPWpGaD
Fingolimod—S1PR4—GPCR downstream signaling—IL2—multiple sclerosis	2.45e-05	0.0002	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CCL5—multiple sclerosis	2.43e-05	0.000198	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CCL5—multiple sclerosis	2.43e-05	0.000198	CbGpPWpGaD
Fingolimod—S1PR5—GPCR downstream signaling—IL2—multiple sclerosis	2.36e-05	0.000192	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—IL2—multiple sclerosis	2.36e-05	0.000192	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—SPP1—multiple sclerosis	2.34e-05	0.000191	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—TYK2—multiple sclerosis	2.33e-05	0.000191	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CCR5—multiple sclerosis	2.27e-05	0.000185	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CXCL10—multiple sclerosis	2.27e-05	0.000185	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—SPP1—multiple sclerosis	2.25e-05	0.000183	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—SPP1—multiple sclerosis	2.25e-05	0.000183	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CD86—multiple sclerosis	2.24e-05	0.000183	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—IL2RA—multiple sclerosis	2.24e-05	0.000183	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism—APOE—multiple sclerosis	2.23e-05	0.000182	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—IL2—multiple sclerosis	2.22e-05	0.000181	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—POMC—multiple sclerosis	2.22e-05	0.000181	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CCL5—multiple sclerosis	2.2e-05	0.00018	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CCR5—multiple sclerosis	2.19e-05	0.000178	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CCR5—multiple sclerosis	2.19e-05	0.000178	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—IL2RA—multiple sclerosis	2.16e-05	0.000176	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—IL2RA—multiple sclerosis	2.16e-05	0.000176	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—IL2—multiple sclerosis	2.14e-05	0.000175	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—IL2—multiple sclerosis	2.14e-05	0.000175	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—IL2—multiple sclerosis	2.14e-05	0.000175	CbGpPWpGaD
Fingolimod—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.11e-05	0.000172	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—APOE—multiple sclerosis	2.07e-05	0.000169	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—SPP1—multiple sclerosis	2.04e-05	0.000167	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—ALB—multiple sclerosis	2.02e-05	0.000165	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—APOE—multiple sclerosis	1.99e-05	0.000162	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—APOE—multiple sclerosis	1.99e-05	0.000162	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CCR5—multiple sclerosis	1.99e-05	0.000162	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CD86—multiple sclerosis	1.98e-05	0.000162	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—IL2RA—multiple sclerosis	1.96e-05	0.00016	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CCL5—multiple sclerosis	1.95e-05	0.000159	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—IL2—multiple sclerosis	1.94e-05	0.000159	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—APOE—multiple sclerosis	1.91e-05	0.000156	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism—POMC—multiple sclerosis	1.91e-05	0.000156	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CD80—multiple sclerosis	1.87e-05	0.000153	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—APOE—multiple sclerosis	1.81e-05	0.000147	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—SPP1—multiple sclerosis	1.81e-05	0.000147	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CD80—multiple sclerosis	1.8e-05	0.000147	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CD80—multiple sclerosis	1.8e-05	0.000147	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—POMC—multiple sclerosis	1.78e-05	0.000145	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CCR5—multiple sclerosis	1.76e-05	0.000143	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism—ALB—multiple sclerosis	1.74e-05	0.000142	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CCL2—multiple sclerosis	1.74e-05	0.000142	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—IL2RA—multiple sclerosis	1.73e-05	0.000141	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—POMC—multiple sclerosis	1.71e-05	0.000139	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—POMC—multiple sclerosis	1.71e-05	0.000139	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—SRM—multiple sclerosis	1.7e-05	0.000139	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—MAPK1—multiple sclerosis	1.7e-05	0.000139	CbGpPWpGaD
Fingolimod—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.7e-05	0.000139	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CCL2—multiple sclerosis	1.67e-05	0.000136	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CCL2—multiple sclerosis	1.67e-05	0.000136	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—POMC—multiple sclerosis	1.64e-05	0.000134	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—MAPK1—multiple sclerosis	1.64e-05	0.000134	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—MAPK1—multiple sclerosis	1.64e-05	0.000134	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CD80—multiple sclerosis	1.63e-05	0.000133	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—APOE—multiple sclerosis	1.6e-05	0.00013	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—TYK2—multiple sclerosis	1.58e-05	0.000129	CbGpPWpGaD
Fingolimod—CYP2E1—Biological oxidations—POMC—multiple sclerosis	1.58e-05	0.000129	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—POMC—multiple sclerosis	1.55e-05	0.000127	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—TYK2—multiple sclerosis	1.52e-05	0.000124	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CCL2—multiple sclerosis	1.52e-05	0.000124	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—TYK2—multiple sclerosis	1.52e-05	0.000124	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—ALB—multiple sclerosis	1.5e-05	0.000122	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—MAPK1—multiple sclerosis	1.49e-05	0.000121	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CD80—multiple sclerosis	1.45e-05	0.000118	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—TYK2—multiple sclerosis	1.38e-05	0.000113	CbGpPWpGaD
Fingolimod—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.38e-05	0.000112	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—POMC—multiple sclerosis	1.37e-05	0.000112	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CCL2—multiple sclerosis	1.34e-05	0.00011	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—IL2—multiple sclerosis	1.31e-05	0.000107	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—IL6—multiple sclerosis	1.31e-05	0.000107	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—IL2—multiple sclerosis	1.26e-05	0.000103	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—IL2—multiple sclerosis	1.26e-05	0.000103	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—IL6—multiple sclerosis	1.26e-05	0.000103	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—IL6—multiple sclerosis	1.26e-05	0.000103	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—MMP9—multiple sclerosis	1.24e-05	0.000101	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—TYK2—multiple sclerosis	1.22e-05	9.96e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—SRM—multiple sclerosis	1.21e-05	9.85e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—CYP24A1—multiple sclerosis	1.2e-05	9.78e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—CYP27B1—multiple sclerosis	1.2e-05	9.78e-05	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—MMP9—multiple sclerosis	1.2e-05	9.76e-05	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—MMP9—multiple sclerosis	1.2e-05	9.76e-05	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—IL2—multiple sclerosis	1.15e-05	9.36e-05	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—IL6—multiple sclerosis	1.14e-05	9.32e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Biological oxidations—POMC—multiple sclerosis	1.12e-05	9.13e-05	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—STAT3—multiple sclerosis	1.1e-05	9.02e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—GPC5—multiple sclerosis	1.1e-05	8.95e-05	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—MMP9—multiple sclerosis	1.09e-05	8.86e-05	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—STAT3—multiple sclerosis	1.06e-05	8.68e-05	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—STAT3—multiple sclerosis	1.06e-05	8.68e-05	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—MYC—multiple sclerosis	1.03e-05	8.38e-05	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—TGFB1—multiple sclerosis	1.02e-05	8.36e-05	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—IL2—multiple sclerosis	1.02e-05	8.29e-05	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—MAPK1—multiple sclerosis	1e-05	8.2e-05	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—MYC—multiple sclerosis	9.88e-06	8.06e-05	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—MYC—multiple sclerosis	9.88e-06	8.06e-05	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—TGFB1—multiple sclerosis	9.86e-06	8.04e-05	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—TGFB1—multiple sclerosis	9.86e-06	8.04e-05	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—MAPK1—multiple sclerosis	9.67e-06	7.89e-05	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—MAPK1—multiple sclerosis	9.67e-06	7.89e-05	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—STAT3—multiple sclerosis	9.66e-06	7.88e-05	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—MMP9—multiple sclerosis	9.61e-06	7.84e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—RRM1—multiple sclerosis	9.09e-06	7.42e-05	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—MYC—multiple sclerosis	8.97e-06	7.32e-05	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—TGFB1—multiple sclerosis	8.95e-06	7.3e-05	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—MAPK1—multiple sclerosis	8.78e-06	7.16e-05	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—STAT3—multiple sclerosis	8.55e-06	6.97e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	8.51e-06	6.94e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	8.51e-06	6.94e-05	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—MYC—multiple sclerosis	7.94e-06	6.48e-05	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—TGFB1—multiple sclerosis	7.92e-06	6.46e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—SRM—multiple sclerosis	7.9e-06	6.44e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—GPC5—multiple sclerosis	7.78e-06	6.35e-05	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—MAPK1—multiple sclerosis	7.77e-06	6.34e-05	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—IL6—multiple sclerosis	7.72e-06	6.3e-05	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—IL6—multiple sclerosis	7.43e-06	6.06e-05	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—IL6—multiple sclerosis	7.43e-06	6.06e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Biological oxidations—POMC—multiple sclerosis	7.32e-06	5.97e-05	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—IL6—multiple sclerosis	6.75e-06	5.5e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—RRM1—multiple sclerosis	6.45e-06	5.26e-05	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—IL6—multiple sclerosis	5.97e-06	4.87e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	5.56e-06	4.54e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	5.56e-06	4.54e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—BCHE—multiple sclerosis	5.22e-06	4.26e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—GPC5—multiple sclerosis	5.09e-06	4.15e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—RRM1—multiple sclerosis	4.22e-06	3.44e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—BCHE—multiple sclerosis	3.7e-06	3.02e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—APOE—multiple sclerosis	3.14e-06	2.56e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—POMC—multiple sclerosis	2.7e-06	2.2e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—ALB—multiple sclerosis	2.46e-06	2.01e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.42e-06	1.98e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—APOE—multiple sclerosis	2.23e-06	1.82e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—POMC—multiple sclerosis	1.91e-06	1.56e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—ALB—multiple sclerosis	1.74e-06	1.42e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—APOE—multiple sclerosis	1.46e-06	1.19e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—POMC—multiple sclerosis	1.25e-06	1.02e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—ALB—multiple sclerosis	1.14e-06	9.31e-06	CbGpPWpGaD
